Journal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 26, Issue 21, Pages 5277-5283Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2016.09.047
Keywords
CCR10; CCL27; Psoriasis; Contact hypersensitivity; Structural alerts
Categories
Ask authors/readers for more resources
Compound 1 ((4-amino-3,5-dichloropheny1)-1-(4-methylpiperidin-1-y1)-4-(2-nitroimidazol-1-y1)-1oxobutane-2-sulfonamido) was discovered to be a 690 nM antagonist of human CCR10 Ca2+ flux. Optimization delivered (2R)-4-(2-cyanopyrrol-1-y1)-S-(1H-indo1-4-y1)-1-(4-methylpiperidin-l-y1)-1oxobutane-2-sulfonamido (eut-22) that is 300 fold more potent a CCR10 antagonist than 1 and eliminates potential toxicity, mutagenicity, and drug-drug-interaction liabilities often associated with nitroaryls and anilines. eut-22 is highly selective over other GPCR's, including a number of other chemokine receptors. Finally, eut-22 is efficacious in the murine DNFB model of contact hypersensitivity. The efficacy of this compound provides further evidence for the role of CCR10 in dermatological inflammatory conditions. (C) 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available